December 31, 2011
2011
- ReadSacchi V. Gefitinib: a pharmacoeconomic profile of its use in patients with Non Small Cell Lung Cancer EGFR+. Farmeconomia e percorsi terapeutici 2011; 12(2): 77-85
- ReadZaniolo O, Iannazzo S, Patrucco GP, Bellini R. Cost-effectiveness evaluations of spinal neuromodulation with ziconotide continuous infusion in cancer pain in a real clinical practice. Farmeconomia e percorsi terapeutici 2011; 12(2): 87-94
- ReadZaniolo O, Carsi M, Iannazzo S. Tiotropium bromide in the routine care of GOLD stage II COPD patients: a pharmaeconomic evaluation. Farmeconomia e percorsi terapeutici 2011; 12(2): 45-52
- ReadZaniolo O, Bettoncelli G, Bosio G, Mantovani L, Pistelli R, Vaghi A, Villa M, Iannazzo S, Bamfi F, Frizzo V, Dal Negro RW. Estimation of economic consequences of GOLD guidelines adoption in the Italian clinical practice. Farmeconomia e percorsi terapeutici 2011; 12(1): 5-19
- ReadDal Negro RW, Pradelli L, Tognella S, Micheletto C, Iannazzo S. Cost-utility of add-on omalizumab in difficult-to-treat allergic asthma in Italy. Eur Ann Allergy Clin Immunol 2011; 43(2): 45-53
- ReadIannazzo S, Pradelli L, Carsi M, Perachino M. Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy. Value Health 2011; 14(1): 80-9
- ReadIannazzo S. Pharmacoeconomic evaluation of the MF59–adjuvanted influenza vaccine in the elderly population in Italy. J Prev Med Hyg 2011; 52(1):1-8
No Comments
Sorry, the comment form is closed at this time.